LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Mast Group Launches MAST ISOPLEX CRE-Art Kit for Rapid Molecular Detection of Carbapenemase Producing Organisms

By LabMedica International staff writers
Posted on 23 Dec 2019
Print article
Illustration
Illustration
Mast Group Ltd. (Liverpool, UK) announced the expansion of its molecular product portfolio with the launch of the new MAST ISOPLEX CRE-ART kit for the rapid molecular detection of carbapenemase producing organisms (CPOs).

Mast is a manufacturer and supplier of diagnostic products for clinical, industrial and veterinary testing. The company manufactures microbiology and molecular biology products, as well as other infectious disease and autoimmune diagnostics, using a variety of technologies.

The new MAST ISOPLEX CRE-ART is a loop mediated isothermal amplification (LAMP) kit for the detection and characterization of the seven most prevalent carbapenemase families: OXA-48, OXA-23, OXA-24/40, KPC, VIM, NDM and IMP. With ready-to-use with lyophilised pellets containing all primers and reagents, it provides rapid results with a 15-minute hands on time and a 30-minute run time. MAST ISOPLEX CRE-ART uses LAMP to provide an alternative to PCR technologies for the molecular detection of CPOs to make testing accessible to laboratories with limited resource and experience.

The company’s additional related MAST products include MAST CARBA PAcE – a rapid, simple and cost-effective solution for carbapenemase detection in Pseudomonas, Acinetobacter and Enterobacterales; MASTDISCS Combi ESBL Set (EUCAST) – with new recommended disc potencies as highlighted by EUCAST; MASTDISCS Combi AmpC, ESBL & Carbapenemase Detection Set - a combination six disc system that has been developed for the detection of Gram-negative resistance in Enterobacterales; MASTDISCS Combi Carba plus – for the detection of carbapenemase and OXA-48 enzyme production in Enterobacterales; and MAST ICT Indirect Carbapenemase Test – a screening test for the detection of carbapenemase production in Enterobacterales, Pseudomonas spp. and Acinetobacter spp.

Related Links:
Mast Group Ltd.

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
New
Gold Member
Plasma Control
Plasma Control Level 1

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more